Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:46 2024-04-16 am EDT 5-day change 1st Jan Change
6,052 INR +0.70% Intraday chart for Dr. Reddy's Laboratories Limited -1.88% +4.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday MT
Dr. Reddy's Launches Migraine Management Device Nerivio in Germany MT
Dr. Reddy's Launches Migraine Management Wearable in Germany MT
Asian Equities Traded in the US as American Depositary Receipts Start Week on Strong Note in Monday Trading MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Dr. Reddy's Laboratories, Bayer Collaborate to Distribute Second Brand of Heart Failure Drug in India MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading, End Week Lower MT
Bayer and Dr. Reddy's Sign A Marketing and Distribution Agreement for Second Brand of Vericiguat in India CI
Asian Equities Traded in the US as American Depositary Receipts Rebound in Early Wednesday Trading MT
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading MT
Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands MT
Dr. Reddy's Laboratories Limited Enters into Exclusive Distribution Partnership with Sanofi Healthcare India Private Limited CI
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
Dr. Reddy's Labs Secures Marketing Rights to Treatment for Hypovolemic Shock in India, Nepal MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading MT
Dr. Reddy's Board to Consider Dividend for Fiscal 2024 MT
Pharmazz Inc. and Dr. Reddy's Laboratories Limited Enter into A Licensing Agreement to Market Centhaquine as A Resuscitative Agent for Hypovolemic Shock in India CI
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
Dr. Reddy?s Laboratories Ltd. Launches Versavo® (Bevacizumab) in United Kingdom CI
Losses Led by IT Drag Indian Equities on Tuesday MT
Dr. Reddy's Laboratories Launches Versavo Drug in UK MT
Chart Dr. Reddy's Laboratories Limited
More charts
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,010 INR
Average target price
6,017 INR
Spread / Average Target
+0.12%
Consensus
  1. Stock Market
  2. Equities
  3. DRREDDY Stock
  4. News Dr. Reddy's Laboratories Limited
  5. Dr Reddy Laboratories : Plans $137 Million Capex for FY22